Abstract |
Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha. Complete healing of lesions occurred in 1 patient; a second had significant regression of the infected area. In the third, the lesion was stabilized twice after application of the preparation and reduced in size after a subsequent treatment. In vitro studies confirmed that isolates from these patients were acyclovir- or acyclovir/ foscarnet-resistant. In addition, they revealed strong synergy between TFT and interferon-alpha for these isolates and for strains with wild-type drug sensitivity profiles. Topical TFT/ interferon-alpha may be of benefit in the therapy of mucocutaneous HSV infections, especially when they are resistant to treatment with systemic antiviral agents.
|
Authors | C J Birch, D P Tyssen, G Tachedjian, R Doherty, K Hayes, A Mijch, C R Lucas |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 166
Issue 1
Pg. 108-12
(Jul 1992)
ISSN: 0022-1899 [Print] United States |
PMID | 1318909
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antiviral Agents
- Interferon Type I
- Recombinant Proteins
- Foscarnet
- Phosphonoacetic Acid
- Trifluridine
- Acyclovir
|
Topics |
- Acquired Immunodeficiency Syndrome
(complications)
- Acyclovir
(pharmacology, therapeutic use)
- Adult
- Antiviral Agents
(pharmacology, therapeutic use)
- Combined Modality Therapy
- Cytopathogenic Effect, Viral
(drug effects)
- Dose-Response Relationship, Drug
- Drug Resistance, Microbial
- Female
- Foscarnet
- Herpes Simplex
(complications, drug therapy, therapy)
- Humans
- Interferon Type I
(pharmacology, therapeutic use)
- Male
- Phosphonoacetic Acid
(analogs & derivatives, pharmacology, therapeutic use)
- Recombinant Proteins
- Recurrence
- Simplexvirus
(drug effects)
- Trifluridine
(pharmacology, therapeutic use)
- Virus Replication
(drug effects)
|